Decision: Favourable

Study Title:

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508deland a Minimal Function Mutation (F/MF)

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Prof. Edward McKone

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Vertex Pharmaceuticals

Scroll to Top